Press releases

The Deinodrop technology will be co-developed by ESPCI and DEINOVE to accelerate the discovery and identification of bacteria producing new...

Emmanuel PETIOT will resign as Chief Executive Officer ("CEO") as of December 31, 2019 Dr. Charles WOLER, Chairman of the Board of...

This new carotenoid has the particularity of absorbing blue light, which is responsible for premature skin ageing, the appearance of skin...

DEINOVE will present DNV3837/DNV3681, its antibiotic candidate targeting both urgent threats to public health and bioterrorism pathogens...

Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections...

DEINOVE strengthens its expertise in the genetic engineering of rare and varied microorganisms to accelerate the discovery and optimization...

New in vitro and clinical efficacy data have been published; Sphingomonas hydrophobicum extract, the active substance of Hebelys®,...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

Major Steven Zumbrun (USAMRIID [1] , U.S. Department of Defense) presented data on the in vitro assessment of DNV3681 against pathogens...

The tests aimed at validating the dosage required have confirmed a very good efficacy of the ingredient The teams are working to develop a...